179 related articles for article (PubMed ID: 37005236)
21. Efficient optimization of high-dose formulation of novel lyophilizates for dry powder inhalation by the combination of response surface methodology and time-of-flight measurement.
Ohori R; Kiuchi S; Sugiyama S; Miyamoto K; Akita T; Yamashita C
Int J Pharm; 2020 May; 581():119255. PubMed ID: 32217154
[TBL] [Abstract][Full Text] [Related]
22. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
23. Optimized pulmonary gene transfection in mice by spray-freeze dried powder inhalation.
Mohri K; Okuda T; Mori A; Danjo K; Okamoto H
J Control Release; 2010 Jun; 144(2):221-6. PubMed ID: 20184930
[TBL] [Abstract][Full Text] [Related]
24. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
25. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
[TBL] [Abstract][Full Text] [Related]
26. Spray freeze drying for dry powder inhalation of nanoparticles.
Ali ME; Lamprecht A
Eur J Pharm Biopharm; 2014 Aug; 87(3):510-7. PubMed ID: 24657824
[TBL] [Abstract][Full Text] [Related]
27. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition.
Liao Q; Yip L; Chow MYT; Chow SF; Chan HK; Kwok PCL; Lam JKW
Int J Pharm; 2019 Apr; 560():144-154. PubMed ID: 30731259
[TBL] [Abstract][Full Text] [Related]
28. Development of a Spray-Dried Formulation of Peptide-DNA Nanoparticles into a Dry Powder for Pulmonary Delivery Using Factorial Design.
Munir M; Kett VL; Dunne NJ; McCarthy HO
Pharm Res; 2022 Jun; 39(6):1215-1232. PubMed ID: 35441318
[TBL] [Abstract][Full Text] [Related]
29. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
[TBL] [Abstract][Full Text] [Related]
30. Effect of formulation and inhaler parameters on the dispersion of spray freeze dried voriconazole particles.
Liao Q; Lam ICH; Lin HHS; Wan LTL; Lo JCK; Tai W; Kwok PCL; Lam JKW
Int J Pharm; 2020 Jun; 584():119444. PubMed ID: 32445908
[TBL] [Abstract][Full Text] [Related]
31. Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction.
Kozáková J; Altay A; Ždímal V; Mašková L; Sonvico F; Quarta E; Rossi A; Buttini F; Colombo G
Drug Dev Ind Pharm; 2019 Oct; 45(10):1664-1673. PubMed ID: 31389270
[TBL] [Abstract][Full Text] [Related]
32. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
33. Dry Powder Inhalers for Proteins Using Cryo-Milled Electrospun Polyvinyl Alcohol Nanofiber Mats.
Ito T; Yamazoe E; Tahara K
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014394
[TBL] [Abstract][Full Text] [Related]
34. Aerosolizable Plasmid DNA Dry Powders Engineered by Thin-film Freezing.
Xu H; Moon C; Sahakijpijarn S; Dao HM; Alzhrani RF; Wang JL; Williams RO; Cui Z
Pharm Res; 2023 May; 40(5):1141-1152. PubMed ID: 36703028
[TBL] [Abstract][Full Text] [Related]
35. Application of void forming index (VFI): Detection of the effect of physical properties of dry powder inhaler formulations on powder cohesion.
Maruyama S; Ando S; Yonemochi E
Int J Pharm; 2020 Oct; 588():119766. PubMed ID: 32800937
[TBL] [Abstract][Full Text] [Related]
36. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
Stegemann S; Faulhammer E; Pinto JT; Paudel A
Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
[TBL] [Abstract][Full Text] [Related]
37. Development of PEGylated chitosan/CRISPR-Cas9 dry powders for pulmonary delivery via thin-film freeze-drying.
Zhang H; Zhang Y; Williams RO; Smyth HDC
Int J Pharm; 2021 Aug; 605():120831. PubMed ID: 34175380
[TBL] [Abstract][Full Text] [Related]
38. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Sinha S; Das SC
Int J Pharm; 2018 Apr; 541(1-2):26-36. PubMed ID: 29458207
[TBL] [Abstract][Full Text] [Related]
39. Influence of Formulation Factors on the Aerosol Performance and Stability of Lysozyme Powders: a Systematic Approach.
Ferrati S; Wu T; Fuentes O; Brunaugh AD; Kanapuram SR; Smyth HDC
AAPS PharmSciTech; 2018 Oct; 19(7):2755-2766. PubMed ID: 29488193
[TBL] [Abstract][Full Text] [Related]
40. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
